Paul D. Brown

RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).

K. Aldape, W. Curran, Meihua Wang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases.

J. Buckner, A. Asher, C. Ménard, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

Susan M. Chang, P. Brown, M. Mehta, 2013, The Lancet. Oncology.

Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes

W. Curran, D. Brachman, P. Brown, 2019, Neurosurgery.

BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.

P. Brastianos, E. Gerstner, E. Galanis, 2023, The New England journal of medicine.

Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.

P. Brown, W. Tomé, G. Bauman, 2022, Practical radiation oncology.

CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design.

K. Aldape, P. Brown, M. J. van den Bent, 2020, Neuro-oncology.